What type of study is this?

September 30, 2025

Figure S1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer

View Full Paper

Ask AI

Bookmark

CDK6 and p-ERK positivity indicates potential biomarkers in advanced triple-negative breast cancer.
Screened samples reveal significant positivity for CDK6 and p-ERK, highlighting their role in tumor progression.
Phase IB study evaluates safety and efficacy of binimetinib and palbociclib in molecularly selected patients.
Findings may inform treatment strategies for patients with advanced cancer, emphasizing targeted therapies.

We only have this paper's title and publication details.

Phase IB trial assesses CDK6 and p-ERK positivity in samples from advanced breast cancer patients, suggesting targeted therapy utility.

Figure S1 shows CDK6 and p-ERK positivity in screened samples

No takes yet. Share an insight, caveat, or question.

Manso et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Phase IB trial assesses CDK6 and p-ERK positivity in samples from advanced breast cancer patients, suggesting targeted therapy utility.

Figure S1 shows CDK6 and p-ERK positivity in screened samples